RxDoctor Payments Data

Alaina Gregory, PA

Physician Assistant · Clearwater, FLNPI 1437536257

Payments from drug & device makers

$1,752in general payments, 2019–2025

Across 81 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$479
  • Idorsia Pharmaceuticals US Inc$250
  • Novo Nordisk$201
  • Neurocrine Biosciences, Inc.$179
  • Amarin Pharma, Inc.$136
  • Lilly USA, LLC$133
  • plus $375 from 12 others

What the payments were for

  • Food & beverage$1,752100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,752 in reported general payments places this provider in the 70th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$69,416
Medicare patients
364
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$31,726
FarxigaDapagliflozin Propanediol19$17,706
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$16,526
EliquisApixaban20$15,582
JardianceEmpagliflozin11$14,183
MounjaroTirzepatide13$13,002
Repatha SureclickEvolocumab12$6,770
Atorvastatin Calcium112$1,362
Albuterol Sulfate HfaAlbuterol Sulfate41$836
SynthroidLevothyroxine Sodium15$630
Nifedipine ErNifedipine15$582
Amlodipine Besylate98$565
Montelukast Sodium37$535
Gabapentin48$522
Celecoxib11$492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$479$34,23245 claims
Novo NordiskOzempic$201$31,72627 claims
PfizerEliquis$18$15,58220 claims
Lilly USA, LLCMounjaro$133$13,00213 claims
AbbVieSynthroid$85$63015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →